A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Clinical trial NCT05385705 · TERMINATED
Trial details
- NCT number
- NCT05385705
- Sponsor
- Vall d'Hebron Institute of Oncology
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-11
- Primary completion
- 2024-07-11
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.